Evidencia de RM de inflamación cardíaca posterior al accidente cerebrovascular (MIRACLE)
Evidencia de imágenes de resonancia magnética de inflamación cardíaca después de un accidente cerebrovascular
The present study is an investigator initiated, single-centre, prospective, proof-of-concept cohort study aiming to enroll 44 patients with acute middle cerebral artery (MCA) ischemic stroke, involving the right (n=22) and left (n=22) MCA territories and 24 control patients with acute focal neurological symptoms but no evidence of acute brain infarct on DWI-MRI.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The present study is an investigator-initiated, single-center, prospective cohort study. The study aims to enroll 44 patients with acute/subacute middle cerebral artery (MCA) ischemic stroke. The investigators will compare inflammatory markers among 44 patients with MCA ischemic stroke within 10 days post-stroke vs. 60±15 days post-stroke. Other measures to be determined at both time points include B-Type Natriuretic Peptide and systemic inflammatory markers.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Diana Ayan, MSc
- Número de teléfono: 35826 +1 519.685.8500
- Correo electrónico: diana.ayan@lhsc.on.ca
Copia de seguridad de contactos de estudio
- Nombre: Jennifer Moussa
- Número de teléfono: 33110 +1 519.685.8500
- Correo electrónico: jennifer.moussa@lhsc.on.ca
Ubicaciones de estudio
-
-
Ontario
-
London, Ontario, Canadá, N6A 5A5
- Reclutamiento
- Heart & Brain Lab, Western University
-
Investigador principal:
- Luciano Sposato, MD, MBA
-
Contacto:
- Jennifer Moussa
- Número de teléfono: 33110 +1(519) 685-8500
- Correo electrónico: jennifer.moussa@lhsc.on.ca
-
Contacto:
- Diana Ayan, MSc
- Número de teléfono: 35826 +1(519) 685-8500
- Correo electrónico: diana.ayan@lhsc.on.ca
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The investigators will include 44 patients with right (n=22) and left (n=22) MCA ischemic stroke. The investigators aim to include at least 50% of female patients. The investigators will include 24 participants in a control group. Participants in the control group will be patients presenting with acute stroke symptoms but no evidence of acute brain infarction on DWI-MRI imaging. Participants will be divided by sex: the investigators aim to enroll 12 female and 12 male participants. The investigators will aim to enroll participants within the same age range as the stroke participants.
Descripción
Inclusion Criteria:
• Acute ischemic stroke in the right or left MCA territory. Acute ischemic stroke is defined as acute onset focal symptoms matching an acute brain infarct documented on Head computed tomography or diffusion-weighted imaging (DWI) MRI of the brain showing restricted diffusion.
Exclusion Criteria:
- History of known atrial fibrillation, prior myocardial infarction, coronary artery disease, heart failure, prior cardiovascular surgery or percutaneous intervention.
- Previous stroke (occurred within 3 months before the index event)
- Impaired renal function defined as a creatinine clearance <97 mL/min in men or <88 mL/min in women, according to the Cockcroft formula.
- hs-TnT >100 on routine acute stroke baseline bloodwork upon admission.
- Clinically or neurologically unstable patients as per the treating physician.
- Ongoing infection or recent infection within the previous 3 months
- Surgery within 3 months before the stroke
- Concurrent and active inflammatory conditions (connective tissue diseases, rheumatological disease, etc.) or use of anti-inflammatory medications
- Pregnancy, Stage IV renal insufficiency, eGFR <30, and any other contraindications to the use of gadolinium.
- Stroke with symptomatic hemorrhagic transformation
- Subjects will be excluded if they fail the LHSC standard MRI screening questionnaire (cardiac pacemakers/wires, aneurysm clips, shunt/surgical clips, shrapnel/bullets, dentures or metal braces, intra-uterine devices, heart valves, ear implants, prostheses, medication patches such as Nicoderm, Habitrol, or Transderm-Nitro, claustrophobia, history of a head or eye injury involving metal fragments.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Cases (Ischemic stroke): Left and right middle cerebral artery ischemic stroke
Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke. |
Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis. Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days. Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days. |
|
Controls (TIA): Patients with acute focal neurological symptoms without brain infarct on MRI.
Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct. |
Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis. Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days. Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The severity of left ventricular myocardial inflammation on cardiac MRI within 10 days post-stroke
Periodo de tiempo: Within 10 days of stroke onset
|
Proportion of left ventricular myocardium showing inflammatory changes on gadolinium-enhanced cardiac MRI |
Within 10 days of stroke onset
|
|
The extent of left ventricular fibrosis measured on gadolinium-enhanced cardiac MRI within 10 days of stroke onset
Periodo de tiempo: Within 10 days of stroke onset
|
Proportion of left ventricular myocardium showing fibrosis on gadolinium-enhanced cardiac MRI |
Within 10 days of stroke onset
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in left ventricular inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Periodo de tiempo: At 60±15 days compared to first 10 days
|
Quantification of left ventricular inflammation measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
|
Change in B-Type Natriuretic Peptide (NT-proBNP) levels in the second measurement performed at 60±15 days post-stroke relative to the plasma sample drawn within 10 days.
Periodo de tiempo: At 60±15 days compared to first 10 days
|
Change in levels of NT-proBNP between 10 and 60±15 days post-stroke |
At 60±15 days compared to first 10 days
|
|
Change in systemic inflammatory markers between 10 and 60±15 days post-stroke
Periodo de tiempo: At 60±15 days compared to first 10 days
|
High-performance protein biomarker panel for following 92 inflammatory biomarkers in pg/mL ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA |
At 60±15 days compared to first 10 days
|
|
Changes in left atrial inflammation measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Periodo de tiempo: At 60±15 days compared to first 10 days
|
Quantification of left atrial inflammation measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
|
Changes in left atrial fibrosis measured on gadolinium-enhanced cardiac MRI at 10 and 60±15 days post-stroke
Periodo de tiempo: At 60±15 days compared to first 10 days
|
Quantification of left atrial fibrosis measured on gadolinium-enhanced cardiac MRI |
At 60±15 days compared to first 10 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Luciano Sposato, MD, London Health Sciences Center, Western University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Carrera
- Condiciones Patológicas, Signos y Síntomas
- Accidente cerebrovascular isquémico
- Inflamación
Otros números de identificación del estudio
- R-21-323
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .